View Item 

Show simple item record

Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy

dc.contributor.authorArnold, Suzanne V.
dc.contributor.authorLi, Shu‐xia
dc.contributor.authorAlexander, Karen P.
dc.contributor.authorSpertus, John A.
dc.contributor.authorNallamothu, Brahmajee K.
dc.contributor.authorCurtis, Jeptha P.
dc.contributor.authorKosiborod, Mikhail
dc.contributor.authorGupta, Aakriti
dc.contributor.authorWang, Tracy Y.
dc.contributor.authorLin, Haiqun
dc.contributor.authorDharmarajan, Kumar
dc.contributor.authorStrait, Kelly M.
dc.contributor.authorLowe, Timothy J.
dc.contributor.authorKrumholz, Harlan M.
dc.date.accessioned2017-11-13T16:41:31Z
dc.date.available2017-11-13T16:41:31Z
dc.date.issued2015-06
dc.identifier.citationArnold, Suzanne V.; Li, Shu‐xia ; Alexander, Karen P.; Spertus, John A.; Nallamothu, Brahmajee K.; Curtis, Jeptha P.; Kosiborod, Mikhail; Gupta, Aakriti; Wang, Tracy Y.; Lin, Haiqun; Dharmarajan, Kumar; Strait, Kelly M.; Lowe, Timothy J.; Krumholz, Harlan M. (2015). "Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy." Journal of the American Heart Association (6): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/139118
dc.publisherWiley Periodicals, Inc.
dc.subject.otherbleeding
dc.subject.othervariation
dc.subject.otheranticoagulation
dc.subject.othermyocardial infarction
dc.titleHospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139118/1/jah31000.pdf
dc.identifier.doi10.1161/JAHA.115.002009
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferenceDangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Mockel M, Caixeta A, Parise H, White H, Stone GW. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONSâ SWITCH analysis. J Am Coll Cardiol. 2011; 57: 2309 â 2316.
dc.identifier.citedreferenceSteg PG, James SK, Atar D, Badano LP, Blomstromâ Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandezâ Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, vanâ t Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with STâ segment elevation. Eur Heart J. 2012; 33: 2569 â 2619.
dc.identifier.citedreferenceHamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent STâ segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent STâ segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 2999 â 3054.
dc.identifier.citedreferenceO’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamisâ Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of STâ elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: e362 â e425.
dc.identifier.citedreferenceWright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Jacobs AK. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/nonâ STâ elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 2022 â 2060.
dc.identifier.citedreferenceEikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and lowâ molecularâ weight heparin in acute coronary syndrome without ST elevation: a metaâ analysis. Lancet. 2000; 355: 1936 â 1942.
dc.identifier.citedreferenceSinnaeve PR, Simes J, Yusuf S, Garg J, Mehta S, Eikelboom J, Bittl JA, Serruys P, Topol EJ, Granger CB. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J. 2005; 26: 2396 â 2403.
dc.identifier.citedreferenceMahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ III, Califf RM. Highâ risk patients with acute coronary syndromes treated with lowâ molecularâ weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005; 294: 2594 â 2600.
dc.identifier.citedreferenceStone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the acute catheterization and urgent intervention triage strategy (ACUITY) trial. Lancet. 2007; 369: 907 â 919.
dc.identifier.citedreferenceAmin AP, Marso SP, Rao SV, Messenger J, Chan PS, House J, Kennedy K, Robertus K, Cohen DJ, Mahoney EM. Costâ effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes. 2010; 3: 358 â 365.
dc.identifier.citedreferenceShahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEATâ PPCI): an openâ label, single centre, randomised controlled trial. Lancet. 2014; 384: 1849 â 1858.
dc.identifier.citedreferenceBurwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, Foody JM. National and state trends in quality of care for acute myocardial infarction between 1994â 1995 and 1998â 1999: the Medicare health care quality improvement program. Arch Intern Med. 2003; 163: 1430 â 1439.
dc.identifier.citedreferencePartovian C, Gleim SR, Mody PS, Li SX, Wang H, Strait KM, Allen LA, Lagu T, Normand SL, Krumholz HM. Hospital patterns of use of positive inotropic agents in patients with heart failure. J Am Coll Cardiol. 2012; 60: 1402 â 1409.
dc.identifier.citedreferenceSafavi KC, Dharmarajan K, Kim N, Strait KM, Li SX, Chen SI, Lagu T, Krumholz HM. Variation exists in rates of admission to intensive care units for heart failure patients across hospitals in the United States. Circulation. 2013; 127: 923 â 929.
dc.identifier.citedreferencePremier Inc. Mission/Vision: What Premier Does. Retrieved from https://www.premierinc.com/about-premier/mission-and-vision. 2015.
dc.identifier.citedreferenceYeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010; 362: 2155 â 2165.
dc.identifier.citedreferenceElixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8 â 27.
dc.identifier.citedreferencePinto DS, Ogbonnaya A, Sherman SA, Tung P, Normand SL. Bivalirudin therapy is associated with improved clinical and economic outcomes in STâ elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database. Circ Cardiovasc Qual Outcomes. 2012; 5: 52 â 61.
dc.identifier.citedreferenceRassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010; 31: 561 â 572.
dc.identifier.citedreferenceAstroulakis Z, Hill JM. Does â switchingâ from heparin to bivalirudin monotherapy result in a bleeding benefit? Eur Heart J Suppl. 2009; 11: C13 â C18.
dc.identifier.citedreferenceStone GW, Mehran R, Goldstein P, Witzenbichler B, Van’t Hof A, Guagliumi G, Hamm CW, Genereux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patientâ level analysis from the HORIZONSâ AMI and EUROMAX trials. J Am Coll Cardiol. 2015; 65: 27 â 38.
dc.identifier.citedreferenceGrilli L, Rampichini C. A multilevel multinomial logit model for the analysis of graduatesâ skills. Stat Methods Appl. 2007; 16: 381 â 393.
dc.identifier.citedreferenceKrumholz HM, Wang Y, Mattera JA, Han LF, Ingber MJ, Roman S, Normand SL. An administrative claims model suitable for profiling hospital performance based on 30â day mortality rates among patients with heart failure. Circulation. 2006; 113: 1693 â 1701.
dc.identifier.citedreferenceBriguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciardelli B. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015; 8: 414 â 423.
dc.identifier.citedreferenceMarso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010; 303: 2156 â 2164.
dc.identifier.citedreferenceXian Y, Chen AY, Thomas L, Roe MT, Subherwal S, Cannon CP, Pollack CV Jr, Fonarow GC, Kosiborod M, Peterson ED, Alexander KP. Sources of hospitalâ level variation in major bleeding among patients with nonâ STâ segment elevation myocardial infarction: a report from the national cardiovascular data registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014; 7: 236 â 243.
dc.identifier.citedreferenceRao SC, Chhatriwalla AK, Kennedy KF, Decker CJ, Gialde E, Spertus JA, Marso SP. Preâ procedural estimate of individualized bleeding risk impacts physiciansâ utilization of bivalirudin during percutaneous coronary intervention. J Am Coll Cardiol. 2013; 61: 1847 â 1852.
dc.identifier.citedreferenceKadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR Action Registryâ GWTG (national cardiovascular data registry acute coronary treatment and intervention outcomes network registryâ get with the guidelines). JACC Cardiovasc Interv. 2010; 3: 1166 â 1177.
dc.identifier.citedreferenceArnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res. 2006; 118: 253 â 262.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah31000.pdf
Size:
449.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.